SPAC targets in the healthcare space typically are a few years away from full commercialization, but shareholders in Exelfin Acquisition Corp. (NASDAQ:XFIN) will get to vote this week on a combination with a medical device company that is already churning out positive EBITDA.
This week, we speak with Brian Sun, Chief Operating Officer of Excelfin and David Kaysen, Senior Advisor and Chief Marketing Officer for Baird Medical.
The two announced a $279 million dollar combination in June 2023. Brian explains why Excelfin diverted its initial focus from fintech to medical devices.
David lays out how Baird has gotten this far through commercialization in China and why it expects successful adoption in the US. With the prospect of tariffs potentially increasing between those two jurisdictions, they also explain how Baird and Excelfin have a plan for that as well.
At the SPAC of Dawn It has clearly taken some time for SPACs to break out from their niche, but SPACs and de-SPACs are suddenly everywhere in current events. As the Russian invasion of Ukraine drags on, one of the most prolific SPAC teams has stepped forward with a letter of intent to take Ukraine’s...
Live Oak Acquisition Corp. V (NASDAQ:LOKVU) has filed for a $200 million IPO that brings another serial SPAC team back to the mix for a generalist search but with a pair of technology deals already in their pocket. The new S-1 also puts Santander on the board for the 2025 SPAC market after it made...
CH4 Natural Solutions (NYSE:MTNE.U) has filed for a $250 million SPAC to bring both the Riverstone sponsor team and underwriter Citigroup back to the market for 2025. The team secured notably sponsor-friendly terms for the vehicle and will not overfund its trust. In fact, along with fellow Friday filer Live Oak V (NASDAQ:LOKVU), these two...
At the SPAC of Dawn Amid a restive market, SPACs have front-loaded their business this week with three of their four votes set for today and tomorrow. One of these is a completion vote, in which Bowen (NASDAQ:BOWN) will try and secure shareholder approval for its combination with Shenzhen Qianzhi BioTechnology just after having gained...
Terms Tracker for the Week Ending January 10, 2025 Welcome to our weekly column where we discuss the findings from our IPO terms tracker based on the previous week’s pricings. This was the first full week in January and the first non-holiday week since December 23rd. All the same, 2025 has started with a bang...